Home / Publications / Modeling of novel CDK7 inhibitors activity by molecular dynamics and free energy perturbation methods

Modeling of novel CDK7 inhibitors activity by molecular dynamics and free energy perturbation methods

Polina Vladimirovna Rusina 1, 2
Polina Vladimirovna Rusina
Ilya Yur'evich Titov 1, 3
Ilya Yur'evich Titov
Maria Vyacheslavovna Panova 1
Maria Vyacheslavovna Panova
Viktor Sergeevich Stroylov 1, 3
Viktor Sergeevich Stroylov
Yana Rasil'evna Abdyusheva 1, 4
Yana Rasil'evna Abdyusheva
Elizaveta Yu Murlatova 1, 4
Elizaveta Yu Murlatova
Igor Svitanko 1, 4
Igor Svitanko
Fedor Nikolaevich Novikov 1, 3
Fedor Nikolaevich Novikov
Published 2020-06-26
CommunicationVolume 30, Issue 4, 430-432
3
Share
Cite this
GOST
 | 
Cite this
GOST Copy
Rusina P. V. et al. Modeling of novel CDK7 inhibitors activity by molecular dynamics and free energy perturbation methods // Mendeleev Communications. 2020. Vol. 30. No. 4. pp. 430-432.
GOST all authors (up to 50) Copy
Rusina P. V., Titov I. Y., Panova M. V., Stroylov V. S., Abdyusheva Y. R., Murlatova E. Yu., Svitanko I., Novikov F. N. Modeling of novel CDK7 inhibitors activity by molecular dynamics and free energy perturbation methods // Mendeleev Communications. 2020. Vol. 30. No. 4. pp. 430-432.
RIS
 | 
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.mencom.2020.07.008
UR - https://mendcomm.colab.ws/publications/10.1016/j.mencom.2020.07.008
TI - Modeling of novel CDK7 inhibitors activity by molecular dynamics and free energy perturbation methods
T2 - Mendeleev Communications
AU - Rusina, Polina Vladimirovna
AU - Titov, Ilya Yur'evich
AU - Panova, Maria Vyacheslavovna
AU - Stroylov, Viktor Sergeevich
AU - Abdyusheva, Yana Rasil'evna
AU - Murlatova, Elizaveta Yu
AU - Svitanko, Igor
AU - Novikov, Fedor Nikolaevich
PY - 2020
DA - 2020/06/26
PB - Mendeleev Communications
SP - 430-432
IS - 4
VL - 30
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2020_Rusina,
author = {Polina Vladimirovna Rusina and Ilya Yur'evich Titov and Maria Vyacheslavovna Panova and Viktor Sergeevich Stroylov and Yana Rasil'evna Abdyusheva and Elizaveta Yu Murlatova and Igor Svitanko and Fedor Nikolaevich Novikov},
title = {Modeling of novel CDK7 inhibitors activity by molecular dynamics and free energy perturbation methods},
journal = {Mendeleev Communications},
year = {2020},
volume = {30},
publisher = {Mendeleev Communications},
month = {Jun},
url = {https://mendcomm.colab.ws/publications/10.1016/j.mencom.2020.07.008},
number = {4},
pages = {430--432},
doi = {10.1016/j.mencom.2020.07.008}
}
MLA
Cite this
MLA Copy
Rusina, Polina Vladimirovna, et al. “Modeling of novel CDK7 inhibitors activity by molecular dynamics and free energy perturbation methods.” Mendeleev Communications, vol. 30, no. 4, Jun. 2020, pp. 430-432. https://mendcomm.colab.ws/publications/10.1016/j.mencom.2020.07.008.

Keywords

CDK7 inhibitors
cyclin-dependent kinase 7
free energy perturbation
hepatotoxicity
molecular dynamics
non-hepatotoxic scaffold
PHA-793887
relative binding free energy

Abstract

Although CDK7 inhibitors are considered to be potential anticancer drugs, all inhibitors developed so far have significant disadvantages preventing their further use. We have developed a new CDK7 inhibitor scaffold lacking hepatotoxicity using molecular dynamics (MD) and free energy perturbation (FEP/MD) methods, and were able to double its binding affinity after additional research. The combination of MD and FEP/MD methods was shown to be a valuable instrument for the development of novel and potent CDK7 inhibitors for anticancer therapy.

References

2.
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
Sun B., Mason S., Wilson R.C., Hazard S.E., Wang Y., Fang R., Wang Q., Yeh E.S., Yang M., Roberts T.M., Zhao J.J., Wang Q.
Oncogene, 2019
3.
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
Sánchez-Martínez C., Lallena M.J., Sanfeliciano S.G., de Dios A.
Bioorganic and Medicinal Chemistry Letters, 2019
4.
NMR screening and studies of target - Ligand interactions
Polshakov V.I., Batuev E.A., Mantsyzov A.B.
Russian Chemical Reviews, 2019
5.
6.
Lavrov M.I., Karlov D.S., Palyulin V.A., Grigoriev V.V., Zamoyski V.L., Brkich G.E., Pyatigorskaya N.V., Zapolskiy M.E.
Mendeleev Communications, 2018
7.
Molecular design of stable diarylnitroxides
Magdesieva T.V., Levitskiy O.A.
Russian Chemical Reviews, 2018
8.
Kuznetsov N.Y., Malishev V.I., Medvedev M.G., Bubnov Y.N.
Mendeleev Communications, 2019
10.
Marjewski A.A., Medvedev M.G., Gerasimov I.S., Panova M.V., Perdew J.P., Lyssenko K.A., Dmitrienko A.O.
Mendeleev Communications, 2018
11.
Lead Finder: An Approach To Improve Accuracy of Protein−Ligand Docking, Binding Energy Estimation, and Virtual Screening
Stroganov O.V., Novikov F.N., Stroylov V.S., Kulkov V., Chilov G.G.
Journal of Chemical Information and Modeling, 2008
12.
Accurate and Reliable Prediction of Relative Ligand Binding Potency in Prospective Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and Force Field
Wang L., Wu Y., Deng Y., Kim B., Pierce L., Krilov G., Lupyan D., Robinson S., Dahlgren M.K., Greenwood J., Romero D.L., Masse C., Knight J.L., Steinbrecher T., Beuming T., et. al.
Journal of the American Chemical Society, 2015
13.
Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing
Brasca M.G., Albanese C., Alzani R., Amici R., Avanzi N., Ballinari D., Bischoff J., Borghi D., Casale E., Croci V., Fiorentini F., Isacchi A., Mercurio C., Nesi M., Orsini P., et. al.
Bioorganic and Medicinal Chemistry, 2010
14.
A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors
Massard C., Soria J., Anthoney D.A., Proctor A., Scaburri A., Pacciarini M.A., Laffranchi B., Pellizzoni C., Kroemer G., Armand J., Balheda R., Twelves C.J.
Cell Cycle, 2011
16.
A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma
Wang C., Jin H., Gao D., Wang L., Evers B., Xue Z., Jin G., Lieftink C., Beijersbergen R.L., Qin W., Bernards R.
Cell Research, 2018
17.
Profound Methyl Effects in Drug Discovery and a Call for New CH Methylation Reactions
Schönherr H., Cernak T.
Angewandte Chemie - International Edition, 2013
18.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012.